Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
Joint Authors
Yoo, So Young
Badrinath, Narayanasamy
Woo, Hyun Young
Heo, Jeong
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-04-20
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis.
Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months.
Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules.
This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.
American Psychological Association (APA)
Yoo, So Young& Badrinath, Narayanasamy& Woo, Hyun Young& Heo, Jeong. 2017. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators of Inflammation،Vol. 2017, no. 2017, pp.1-12.
https://search.emarefa.net/detail/BIM-1188412
Modern Language Association (MLA)
Yoo, So Young…[et al.]. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators of Inflammation No. 2017 (2017), pp.1-12.
https://search.emarefa.net/detail/BIM-1188412
American Medical Association (AMA)
Yoo, So Young& Badrinath, Narayanasamy& Woo, Hyun Young& Heo, Jeong. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators of Inflammation. 2017. Vol. 2017, no. 2017, pp.1-12.
https://search.emarefa.net/detail/BIM-1188412
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1188412
